REG - Proteome Sciences - Notice of Results

Proteome SciencesAnnouncement

16/03/2020 07:00

For best results when printing this announcement, please click on link below:
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20200316:nRSP1825Ga

RNS Number : 1825G  Proteome Sciences PLC  16 March 2020

 
16 March 2020

 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

 

Notice of Results

 

The Directors of Proteome Sciences look forward to updating shareholders on
the Company's performance, and on the outlook for 2020, at the time of
announcing the 2019 full year results which are scheduled for release on 31
March 2020.

Annual General Meeting

The Annual General Meeting of the Company will take place at the offices of
Allenby Capital, 5 St Helen's Place, London EC3A 6AB, at 2.30pm on 29 April
2020.  Formal notice of such will be posted to shareholders with the annual
report in April.

 

For further information please contact:

 Proteome Sciences plc
 Dr Ian Pike, Interim Chief Executive Officer  Tel: +44 (0)20 7043 2116

 Richard Dennis, Chief Commercial Officer

 Allenby Capital Limited (AIM Nominated Adviser & Broker)
 John Depasquale / Jeremy Porter               Tel: +44 (0) 20 3328 5656

About Proteome Sciences plc. (www.proteomics.com (http://www.proteomics.com/)
)

Proteome Sciences plc is a specialist provider of contract proteomics services
to enable drug discovery, development and biomarker identification, and
employs proprietary workflows for the optimum analysis of tissues, cells and
body fluids.  SysQuant® and TMT®MS2 are unbiased methods for identifying
and contextualising new targets and defining mechanisms of biological
activity, while analysis using Super-Depletion and TMTcalibrator™ provides
access to over 8,500 circulating plasma proteins for the discovery of
disease-related biomarkers. Targeted assay development using mass spectrometry
delivers high sensitivity, interference-free biomarker analyses in situations
where standard ELISA assays are not available.

The Company has its headquarters in London, UK, with laboratory facilities in
Frankfurt, Germany.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.   END  NORFFFSFVTIVLII